Table 2.
COVID-19 Infection Symptoms, Main Laboratory Parameters and Treatment in the First and the Second COVID-19 Infection Waves
| Overall (n = 52) | First COVID-19 wave (n = 28) | Second COVID-19 wave (n = 24) | P value | |
|---|---|---|---|---|
| COVID-19 infection symptoms, n (%)FeverCoughFatigueDyspneaDiarrheaRhinorrheaMusculoskeletal painAnosmiaDiaphoresisNausea/vomitingHeadacheAbsence of symptoms | 39 (75)29 (74)24 (62)13 (33)14 (36)9 (23)6 (15)10 (26)3 (8)3 (8)1 (3)3 (8)13 (25) | 23 (82)18 (78)16 (70)11 (48)9 (39)7 (30)4 (17)4 (17)2 (9)2 (9)1 (4)05 (18) | 16 (67)11 (69)8 (50)2 (12)5 (31)2 (12)2 (12)6 (37)1 (6)1 (16)03 (19)8 (33) | 0.199 |
| Neutrophil count, x109/L, median(range)≥0.5 × 199/L<0.5 × 109/L | 1.7 (0–18)39/51 (77)12/51 (23) | 1.4 (0–6.5)17 (61)11 (39) | 2.9 (0–18)22/23 (96)1/23 (4) | 0.1250.003 |
| Lymphocyte count, x109/L, median (range)≥0.5 × 199/L<0.5 × 109/L | 0.5 (0–5.9)27/51 (53)24/51 (47) | 0.3 (0–1.5)10 (36)18 (64) | 1.2 (0–5.9)17/23 (74)6/23 (26) | 0.0080.007 |
| C-reactive protein, mg/L, median (range) | 22.5 (0.04–311.7) | 28.7 (0.9–311.7) | 13 (0.04–194) | 0.227 |
| D-dimer, ng/mL, median (range)a | 690 (120–31,200) | 690 (120–31,200) | 857.5 (210–10,381) | 1.000 |
| Treatment of COVID-19 infection, n (%)Hydroxychloroquine/chloroquineAzithromycinLopinavir-ritonavirRemdesivirTocilizumabSiltuximabConvalescent serumRibavirinCorticosteroids | 34 (65)24 (71)11 (32)14 (41)4 (12)11 (32)1 (3)3 (9)1 (3)12 (35) | 25 (89)24 (96)11 (44)14 (56)2 (8)8 (32)1 (4)1 (4)05 (20) | 9 (37)0002 (22)3 (33)02 (22)1 (11)7 (78) | <0.001 |
| Oxygen support, n (%) | 20 (38) | 12 (43) | 8 (33) | 0.482 |
| Intensive care unit (ICU) support, n (%) | 11 (21) | 7 (25)b | 4 (17) | 0.463 |
| Days in ICU, median (range) | 16 (1–47) | 16 (1–47) | 21 (11–30) | 1.000 |
ICU = intensive care unit.
a
n = 34.
b
In 1 additional patient ICU support was not provided due to advanced age and poor general status.